Stock XENE XENON PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Xenon Pharmaceuticals Inc.

Equities

XENE

CA98420N1050

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 01:53:35 2024-04-25 pm EDT 		5-day change 1st Jan Change
40.7 USD +3.04% Intraday chart for Xenon Pharmaceuticals Inc. +1.02% -11.59%
Mar. 11 Transcript : Xenon Pharmaceuticals Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 11:20 AM
Mar. 08 Xenon Pharmaceuticals Insider Sold Shares Worth $330,290, According to a Recent SEC Filing MT

Business Summary

Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).

Number of employees: 255

Managers

Managers TitleAgeSince
Ian Mortimer CEO
 Chief Executive Officer 48 13-10-20
Simon Pimstone FOU
 Founder 56 96-11-04
Sherry Aulin DFI
 Director of Finance/CFO 40 10-12-31
Christopher Kenney CTO
 Chief Tech/Sci/R&D Officer - 21-08-22
Sheila M. Grant CTO
 Chief Tech/Sci/R&D Officer - 20-07-31
Jodi Regts IRO
 Public Communications Contact - 15-11-30
Chris von Seggern PRN
 Corporate Officer/Principal - 20-08-16
Andrea DiFabio LAW
 General Counsel 55 22-11-06
James Empfield PRN
 Corporate Officer/Principal - 16-01-31
Robin Sherrington PRN
 Corporate Officer/Principal 63 01-02-28

Members of the board

Members of the board TitleAgeSince
Clarence Machado BRD
 Director/Board Member 60 20-11-04
Mohammad Azab BRD
 Director/Board Member 68 03-09-30
Justin Gover BRD
 Director/Board Member 53 23-08-07
Gary Patou BRD
 Director/Board Member 65 03-12-31
Simon Pimstone FOU
 Founder 56 96-11-04
Steven Gannon BRD
 Director/Board Member 62 15-05-20
Ian Mortimer CEO
 Chief Executive Officer 48 13-10-20
Dawn Svoronos BRD
 Director/Board Member 70 16-09-26
Elizabeth Garofalo BRD
 Director/Board Member 66 21-06-02
Gillian Cannon BRD
 Director/Board Member 60 23-08-07

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 75,432,482 74,047,334 ( 98.16 %) 0 98.16 %

Shareholders

NameEquities%Valuation
Avoro Capital Advisor LLC
7.512 %
5,666,666 7.512 % 244 M $
Fidelity Management & Research Co. LLC
7.498 %
5,655,922 7.498 % 243 M $
Driehaus Capital Management LLC
5.760 %
4,345,180 5.760 % 187 M $
Wellington Management Co. LLP
5.518 %
4,162,654 5.518 % 179 M $
POLAR CAPITAL HOLDINGS PLC
4.065 %
3,066,628 4.065 % 132 M $
Capital Research & Management Co. (World Investors)
3.555 %
2,681,537 3.555 % 115 M $
Capital Research & Management Co. (International Investors)
3.255 %
2,455,683 3.255 % 106 M $
Commodore Capital LP
2.874 %
2,167,793 2.874 % 93 M $
Paradigm BioCapital Advisors LP
2.820 %
2,127,400 2.820 % 92 M $
Pictet Asset Management Holding SA
2.705 %
2,040,400 2.705 % 88 M $

Company contact information

Xenon Pharmaceuticals, Inc.

3650 Gilmore Way Suite 200

V5G 4W8, Burnaby

+604 484 3300

http://www.xenon-pharma.com
address Xenon Pharmaceuticals Inc.(XENE)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
39.5 USD
Average target price
57.44 USD
Spread / Average Target
+45.42%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
XENON PHARMACEUTICALS INC. Stock Xenon Pharmaceuticals Inc.
-12.22% 2.98B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.97% 104B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+2.03% 97.42B
ARGENX SE Stock argenx SE
+0.79% 22.2B
BIONTECH SE Stock BioNTech SE
-17.73% 21.23B
GENMAB A/S Stock Genmab A/S
-11.11% 18.33B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.83% 16.35B
BEIGENE, LTD. Stock BeiGene, Ltd.
-16.02% 15.06B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.68% 13.98B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+35.09% 11.66B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. XENE Stock
  4. Company Xenon Pharmaceuticals Inc.